Get the Stockscreener App
2.75
0.36%
-0.010
After Hours:
2.80
0.05
+1.82%
Okyo Pharma Limited stock is traded at $2.75, with a volume of 28,744.
It is down -0.36% in the last 24 hours and up +11.34% over the past month.
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
See More
Previous Close:
$2.76
Open:
$2.77
24h Volume:
28,744
Relative Volume:
0.16
Market Cap:
$93.05M
Revenue:
-
Net Income/Loss:
$-13.27M
P/E Ratio:
-16.77
EPS:
-0.164
Net Cash Flow:
$-7.70M
1W Performance:
-8.03%
1M Performance:
+11.34%
6M Performance:
+161.90%
1Y Performance:
+103.70%
1-Day Range:
$2.70
$2.7816
1-Week Range:
$2.67
$2.9803
52-Week Range:
$0.8075
$3.11
Okyo Pharma Limited Stock (OKYO) Company Profile
Compare OKYO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
2.75 | 103.81M | 0 | -13.27M | -7.70M | -0.164 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Okyo Pharma Limited Stock (OKYO) Latest News
OKYO Pharma Limited Stock Analysis and ForecastMarket-beating returns - PrintWeekIndia
What analysts say about OKYO Pharma Limited stockMassive stock growth - PrintWeekIndia
Will OKYO Pharma Limited stock benefit from AI tech trendsExplosive market performance - jammulinksnews.com
What institutions are buying OKYO Pharma Limited stock nowConsistently exceptional gains - jammulinksnews.com
OKYO Pharma reports promising phase 2 results for urcosimod in neuropathic corneal pain - Pharmafile
What drives OKYO Pharma Limited stock priceAccelerated wealth expansion - Autocar Professional
Is OKYO Pharma Limited a good long term investmentPhenomenal trading returns - Autocar Professional
OKYO Pharma Secures $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain - VisionMonday.com
OKYO Pharma CEO details positive results from Phase 2 urcosimod trialICYMI - Proactive financial news
OKYO Pharma Secures $1.9M Non-Dilutive Funding to Advance Urcosimod Development - AInvest
OKYO Pharma announces positive results from phase 2 trial of urcosimod for neuropathic corneal pain - Ophthalmology Times
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding - GlobeNewswire
OKYO Pharma receives $1.9 million non-dilutive funding for lead drug development - Investing.com Nigeria
Small cap wrap: Digi Power X, American Resources, OKYO Pharma, Lisata Therapeutics... - Proactive financial news
OKYO Slides Despite Fresh R&D Funding - Baystreet.ca
OKYO Pharma secures $1.9 million in non-dilutive funding for eye drug - Investing.com Canada
Okyo Pharma Obtains $1.9 Million Non-Dilutive Funding - MarketScreener
OKYO Pharma Secures $1.9 Million to Boost Urcosimod Development - TipRanks
OKYO Pharma bolsters ocular pain program with $1.9M non-dilutive financing - Proactive financial news
OKYO Pharma secures $1.9 million in non-dilutive funding for eye drug By Investing.com - Investing.com South Africa
OKYO’s Market Whiplash: 86.16% YTD Rise, -1.66% Plunge in 30 Days - investchronicle.com
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain - MarketScreener
OKYO Secures $1.9M to Fast-Track Revolutionary Eye Pain Drug with No Current FDA Treatment - Stock Titan
OKYO Pharma stock maintains Buy rating at H.C. Wainwright on positive trial data By Investing.com - Investing.com South Africa
OKYO Pharma stock maintains Buy rating at H.C. Wainwright on positive trial data - Investing.com Australia
OKYO Pharma Limited Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain - MarketScreener
OKYO Pharma Receives Positive Buy Rating from H.C. Wainwright - AInvest
Positive Buy Rating for OKYO Pharma Driven by Promising Phase 2 Trial Results and FDA Fast Track Designation - TipRanks
Okyo Pharma Limited Stock (OKYO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):